FDA Approves AMGN's 1st Biosimilar, MRNS On Track, All Ears For DRRX, PTIE

Shares of Marinus Pharmaceuticals Inc. (MRNS) have gained over 35% in the last seven trading days in the run-up to the exploratory phase II study results of Ganaxolone, scheduled for this month.

from RTT - Biotech http://ift.tt/2dl9Dp4
via IFTTT